Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial

Julien Freitag, Dan Bates, James Wickham, Kiran Shah, Leesa Huguenin, Abi Tenen, Kade Paterson, Richard Boyd

Research output: Contribution to journalArticle

7 Downloads (Pure)

Abstract

AIM:
To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis.
METHODS:
30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106 ADMSCs at baseline and 6 months). The third group served as control and continued conservative management.
RESULTS:
No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression.
CONCLUSION:
Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression.
Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalRegenerative Medicine
DOIs
Publication statusPublished - 14 Feb 2019

Fingerprint

Knee Osteoarthritis
Cell- and Tissue-Based Therapy
Stem cells
Mesenchymal Stromal Cells
Randomized Controlled Trials
Disease Progression
Pain
Injections
Therapeutics
Joints
Magnetic Resonance Imaging

Cite this

Freitag, Julien ; Bates, Dan ; Wickham, James ; Shah, Kiran ; Huguenin, Leesa ; Tenen, Abi ; Paterson, Kade ; Boyd, Richard. / Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis : a randomized controlled trial. In: Regenerative Medicine. 2019 ; pp. 1-18.
@article{80a83798ffae4d7cba5d830bd9dbde1d,
title = "Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial",
abstract = "AIM:To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis.METHODS:30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106 ADMSCs at baseline and 6 months). The third group served as control and continued conservative management.RESULTS:No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression.CONCLUSION:Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression.",
author = "Julien Freitag and Dan Bates and James Wickham and Kiran Shah and Leesa Huguenin and Abi Tenen and Kade Paterson and Richard Boyd",
year = "2019",
month = "2",
day = "14",
doi = "10.2217/rme-2018-0161",
language = "English",
pages = "1--18",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd",

}

Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis : a randomized controlled trial. / Freitag, Julien; Bates, Dan; Wickham, James; Shah, Kiran; Huguenin, Leesa; Tenen, Abi; Paterson, Kade; Boyd, Richard.

In: Regenerative Medicine, 14.02.2019, p. 1-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis

T2 - a randomized controlled trial

AU - Freitag, Julien

AU - Bates, Dan

AU - Wickham, James

AU - Shah, Kiran

AU - Huguenin, Leesa

AU - Tenen, Abi

AU - Paterson, Kade

AU - Boyd, Richard

PY - 2019/2/14

Y1 - 2019/2/14

N2 - AIM:To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis.METHODS:30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106 ADMSCs at baseline and 6 months). The third group served as control and continued conservative management.RESULTS:No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression.CONCLUSION:Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression.

AB - AIM:To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis.METHODS:30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106 ADMSCs at baseline and 6 months). The third group served as control and continued conservative management.RESULTS:No serious adverse events were observed. Both treatment groups receiving ADMSCs showed clinically significant pain and functional improvement at completion of follow-up at 12 months. Radiological analysis using the Magnetic Resonance Imaging Osteoarthritis Knee Score indicated modification of disease progression.CONCLUSION:Autologous ADMSC therapy appears to be a safe and effective therapy for knee osteoarthritis and may have the potential to prevent disease progression.

U2 - 10.2217/rme-2018-0161

DO - 10.2217/rme-2018-0161

M3 - Article

SP - 1

EP - 18

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

ER -